Associated Papers
Precision Targeting in Metastatic Prostate Cancer: Molecular Insights to Therapeutic Frontiers.
Kwon WA et al.
Biomolecules, 2025
Structural perspectives on the androgen receptor, the elusive shape-shifter.
Johnson MJ et al.
Steroids, 2024
Unravelling the Role of Iroquois Homeobox 4 and its Interplay with Androgen Receptor in Prostate Cancer.
Janaththani P et al.
Research Square, 2023
Androgen receptor transcriptional activity is required for heregulin-1β-mediated nuclear localization of the HER3/ErbB3 receptor tyrosine kinase.
Jathal MK et al.
The Journal of Biological Chemistry, 2023
Symphony in the crowd: Key genetic alterations in prostate cancer.
Masud N
Cancer Innovation, 2023
A hotspot for posttranslational modifications on the androgen receptor dimer interface drives pathology and anti-androgen resistance.
Alegre-Martí A et al.
Science Advances, 2023
Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer.
Thiyagarajan T et al.
Proceedings of the National Academy of Sciences of the United States of America, 2023
Structural and molecular insights into the mechanism of resistance to enzalutamide by the clinical mutants in androgen receptor (AR) in castration-resistant prostate cancer (CRPC) patients.
Khan A et al.
International Journal of Biological Macromolecules, 2022
Genomic Profiling of Prostate Cancer: An Updated Review.
Hatano K et al.
The World Journal of Men's Health, 2022
Biomarkers of Castrate Resistance in Prostate Cancer: Androgen Receptor Amplification and T877A Mutation Detection by Multiplex Droplet Digital PCR.
Young FP et al.
Journal of Clinical Medicine, 2022
Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies.
Jacob A et al.
Cancers, 2021
Androgen Receptor-Mediated Nuclear Transport of NRDP1 in Prostate Cancer Cells Is Associated with Worse Patient Outcomes.
Steele T et al.
Cancers, 2021
Analysis of the binding modes of the first- and second-generation antiandrogens with respect to F876L mutation.
Shao G et al.
Chemical Biology & Drug Design, 2021
The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on Therapy.
Messner EA et al.
Biomedicines, 2020
Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants.
Banuelos CA et al.
Cancers, 2020
Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer.
Narayanan R
Asian Journal of Urology, 2020
Novel compound variants of the AR and MAP3K1 genes are related to the clinical heterogeneity of androgen insensitivity syndrome.
Cheng Y et al.
Bioscience Reports, 2020
AR mRNA stability is increased with AR-antagonist resistance via 3'UTR variants.
Dart DA et al.
Endocrine Connections, 2020
New Insights into the Binding Mechanism of Co-regulator BUD31 to AR AF2 Site: Structural Determination and Analysis of the Mutation Effect.
Song T et al.
Current Computer-aided Drug Design, 2020
Quantitative Evaluation of the Transcriptional Activity of Steroid Hormone Receptor Mutants and Variants Using a Single Vector With Two Reporters and a Receptor Expression Cassette.
Ji H et al.
Frontiers in Endocrinology, 2020
Loss of Fibroblast-Dependent Androgen Receptor Activation in Prostate Cancer Cells is Involved in the Mechanism of Acquired Resistance to Castration.
Ishii K et al.
Journal of Clinical Medicine, 2019
Non-canonical dimerization of the androgen receptor and other nuclear receptors: implications for human disease.
Jiménez-Panizo A et al.
Endocrine-related Cancer, 2019
Detecting predictive androgen receptor modifications in circulating prostate cancer cells.
Steinestel J et al.
Oncotarget, 2019
Liquid Biopsy to Identify Actionable Genomic Alterations.
Ou SI et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, 2018
Overexpression of p54nrb/NONO induces differential EPHA6 splicing and contributes to castration-resistant prostate cancer growth.
Yamamoto R et al.
Oncotarget, 2018
Structural Changes Due to Antagonist Binding in Ligand Binding Pocket of Androgen Receptor Elucidated Through Molecular Dynamics Simulations.
Sakkiah S et al.
Frontiers in Pharmacology, 2018
Clinical relevance of androgen receptor alterations in prostate cancer.
Jernberg E et al.
Endocrine Connections, 2017
Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities.
Alyamani M et al.
Cell Chemical Biology, 2017
CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC.
Stice JP et al.
Molecular Cancer Research : Mcr, 2017
Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer.
Thomas JD et al.
Cancer Research, 2017
LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.
Nguyen HM et al.
The Prostate, 2017
Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine.
Alvarez-Cubero MJ et al.
Molecular Diagnosis & Therapy, 2017
Structure of the homodimeric androgen receptor ligand-binding domain.
Nadal M et al.
Nature Communications, 2017
The fluorescent two-hybrid assay for live-cell profiling of androgen receptor modulators.
Bogner J et al.
The Journal of Steroid Biochemistry and Molecular Biology, 2017
Functional Impact of Novel Androgen Receptor Mutations on the Clinical Manifestation of Androgen Insensitivity Syndrome.
Petroli RJ et al.
Sexual Development : Genetics, Molecular Biology, Evolution, Endocrinology, Embryology, and Pathology of Sex Determination and Differentiation, 2017
Discovery Proteomics Identifies a Molecular Link between the Coatomer Protein Complex I and Androgen Receptor-dependent Transcription.
Hsiao JJ et al.
The Journal of Biological Chemistry, 2016
Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.
Imamura Y et al.
International Journal of Urology : Official Journal of the Japanese Urological Association, 2016
The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide.
Prekovic S et al.
Molecular Cancer Therapeutics, 2016
Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.
Coleman DJ et al.
Oncotarget, 2016
Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
Kato M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
Mutational analysis of the androgen receptor gene in two Chinese families with complete androgen insensitivity syndrome.
Wang S et al.
Experimental and Therapeutic Medicine, 2016
BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients.
Sugawara T et al.
Oncotarget, 2016
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.
Lallous N et al.
Genome Biology, 2016
DiMeX: A Text Mining System for Mutation-Disease Association Extraction.
Mahmood AS et al.
Plos One, 2016
Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Crona DJ et al.
Clinical Pharmacology and Therapeutics, 2015
RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance.
Miyamoto DT et al.
Science (new York, N.y.), 2015
Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN.
Li H et al.
Oncotarget, 2015
High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB et al.
European Urology, 2015
Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
Savoy RM et al.
Endocrine-related Cancer, 2015
Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment.
Yadav SS et al.
Urologic Oncology, 2015